Another significant study on the combination of Curcumin C3 Complex® and BioPerine®, Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: Results of a randomized controlled trial, by researchers at University of Medical Sciences, Mashhad, Iran, has been published in Complementary Therapies in Medicine 2014; 22(5): 851-857.
This study is the first trial investigating the efficacy and safety of adjunctive therapy with Curcuminoids-Piperinecombination in patients with metabolic syndrome, receiving standard treatment. The results of the trial supported the effectiveness of the adjunctive therapy with significant decrease in serum concentration LDL-C, non-HDL-C, total cholesterol, triglyceride, Lp(a) and elevation in serum concentration of HDL-C in patients in comparison to the standard therapy alone. The present study also encouraged the efficacy of use of co-administering BioPerine® as a bioavailability enhancer.
"This research indicates additional benefits of Curcumin beyond inflammation, giving increased value to C3 Complex as the body of science grows" said Shaheen Majeed, Sabinsa Marketing Director. "And once again the C3 Complex and BioPerine® combination has been shown to be a safe and effective supplement blend that can help keep people healthy."
